CompletedPhase 1NCT00018018
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency
Studying Severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Human Genome Research Institute (NHGRI)
- Principal Investigator
- Robert A Sokolic, M.D., M.DNational Human Genome Research Institute (NHGRI)
- Intervention
- CD34+ cells transduced with ADA retrovir(drug)
- Enrollment
- 8 enrolled
- Eligibility
- All sexes
- Timeline
- 2001 – 2014
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00018018 on ClinicalTrials.govOther trials for Severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05651113The Experience of Screening for SCIDKing's College London
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT01852370Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesPaul Szabolcs
- ENROLLING BY INVITATIONNCT01186913Natural History Study of SCID DisordersNational Institute of Allergy and Infectious Diseases (NIAID)